近日,《柳叶刀肿瘤学》(The Lancet Oncology)在线发表了迄今为止较大的TRK融合癌症患者数据集。该数据集为评估拜耳精准肿瘤学药物Vitrakvi(larotrectinib)治疗TRK融合癌症成人及儿科患者的临床数据。文章标题为:Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials。
原文出处:Updated data on Vitrakv (larotrectinib) confirm clinical efficacy with high response rates and durable responses as well as a good safety profile to date in children and adults with TRK fusion cancer